Balyasny Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADPT
Balyasny Asset Management's ADPT Position: Q1 2026 in Review
Balyasny Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2026, closing a stake of 426,462 shares — an estimated $6.93M sold.
Balyasny Asset Management first reported a position in ADPT in Q4 2019 and held it in 12 quarters. The position peaked at $12.7M in Q4 2019. 298 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.
- Balyasny Asset Management reported no remaining Adaptive Biotechnologies position as of Q1 2026 after selling out during the quarter.
- Balyasny Asset Management sold 426,462 Adaptive Biotechnologies shares in Q1 2026, an estimated $6.93M.
- Balyasny Asset Management first reported a position in Adaptive Biotechnologies in Q4 2019 and held it in 12 quarters.
- Balyasny Asset Management's Adaptive Biotechnologies position peaked at $12.7M in Q4 2019.
- 298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.